Skip to Main Content

Author Details

Alexandre Puissant
Universite de Paris, INSERM, CNRS
2007
71
32
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36794507Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia <i>FLT3</i>-ITD patients.Haematologica2023
36711936MCB-613 exploits a collateral sensitivity in drug resistant <i>EGFR</i>-mutant non-small cell lung cancer through covalent inhibition of KEAP1.bioRxiv2023
34341479Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.Leukemia2022
35474100Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.Leukemia2022
35668193P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.Nat Cancer2022
35791696Walking the Tightrope: Balancing Delicate Inflammation Response to Eradicate Acute Myeloid Leukemia.Cancer Discov2022
35523579Tumor Lysis Syndrome and AKI: Beyond Crystal Mechanisms.J Am Soc Nephrol2022
35750691A multiparametric niche-like drug screening platform in acute myeloid leukemia.Blood Cancer J2022
36570694Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively.Hemasphere2022
35947955Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance.Cell Rep2022
36151081Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML.Blood Cancer J2022
35148910Endothelial cells: major players in acute myeloid leukaemia.Blood Rev2022
35138899Screening of ETO2-GLIS2-induced Super Enhancers identifies targetable cooperative dependencies in acute megakaryoblastic leukemia.Sci Adv2022
33790022Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor.Sci Transl Med2021
32344427CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia.Blood2020
32665699Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML.Leukemia2020
32826232The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.Cancer Discov2020
32847013Drug Resistance in Hematological Malignancies.Int J Mol Sci2020
32203462Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer.Nat Genet2020
30390009Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML.Leukemia2019
31751766BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias.Leuk Res2019
30607021LAMP2 expression dictates azacytidine response and prognosis in MDS/AML.Leukemia2019
29535430Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.Leukemia2018
30517893HER2 Signaling Hijacks the Creatine Shuttle to Fuel Breast Cancer Cell Growth.Cell Metab2018
29515000Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.Sci Transl Med2018
27956388Autophagy, a key mechanism of oncogenesis and resistance in leukemia.Blood2017
28191887The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.Nat Med2017
28367807[Autophagy, a key player in leukemogenesis and a therapeutic target in hematopoietic malignancies].Med Sci (Paris)2017
28881711Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.Oncotarget2017
26999641Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.Oncogene2016
27455953BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.J Exp Med2016
27325891Targeting MTHFD2 in acute myeloid leukemia.J Exp Med2016
26315286Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.Oncotarget2015
24282218MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.Blood2014
25058423A new posttranslational regulation of REDD1/DDIT4 through cleavage by caspase 3 modifies its cellular function.Cell Death Dis2014
25051369The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells.Oncotarget2014
24525236SYK is a critical regulator of FLT3 in acute myeloid leukemia.Cancer Cell2014
23238567Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death.Cell Death Differ2013
24067364Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties.Cell Cycle2013
23770013In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling.Cancer Cell2013
23430699Targeting MYCN in neuroblastoma by BET bromodomain inhibition.Cancer Discov2013
23535559SYK regulates mTOR signaling in AML.Leukemia2013
22143671The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.Leukemia2012
23238683All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.Oncotarget2012
22860231When autophagy meets cancer through p62/SQSTM1.Am J Cancer Res2012
22498477The anti-apoptotic Bcl-B protein inhibits BECN1-dependent autophagic cell death.Autophagy2012
22467682Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.J Mol Cell Biol2012
22555455The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production.Cell Death Differ2012
22577154BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.Oncotarget2012
22595539Ultrasound-assisted one-pot synthesis of anti-CML nucleosides featuring 1,2,3-triazole nucleobase under iron-copper catalysis.Ultrason Sonochem2012
  • 1 - 50 of 71

Recommended Authors

Hongying Zhang
The Second Affiliated Hospital of Nanchang University
Career Start Year 2018
Number of shared co-authors 0
Haijiao Zhang
Oregon Health & Science University, Knight Cancer Institute
Career Start Year 2017
Number of shared co-authors 3
Jonathan M Ahmann
Huntsman Cancer Institute, The University of Utah
Career Start Year 2017
Number of shared co-authors 0
Veronique Litalien
Walter and Eliza Hall Institute of Medical Research
Career Start Year 2016
Number of shared co-authors 0
Ashok Kumar Jayavelu
German Cancer Research Center (DKFZ)
Career Start Year 2014
Number of shared co-authors 5
Anna Senina
Huntsman Cancer Institute, The University of Utah
Career Start Year 2013
Number of shared co-authors 1
Subbaiah Chary Nimmagadda
University Hospital Luebeck
Career Start Year 2012
Number of shared co-authors 1
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 1
Yang Chen
The University of Texas MD Anderson Cancer Center
Career Start Year 2008
Number of shared co-authors 0
Brett M Stevens
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 2
Shweta Joshi
Moores Cancer Center, University of California
Career Start Year 2007
Number of shared co-authors 0
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 2
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 3
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Career Start Year 2004
Number of shared co-authors 1
Mateusz Koptyra
Children's Hospital of Philadelphia
Career Start Year 2004
Number of shared co-authors 0
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Career Start Year 2002
Number of shared co-authors 11
Phillip M Clair
Huntsman Cancer Institute, The University of Utah
Career Start Year 2001
Number of shared co-authors 0
Mark A Gregory
University of Colorado Anschutz Medical Campus
Career Start Year 2000
Number of shared co-authors 1
Rose Hurren
Princess Margaret Cancer Centre
Career Start Year 1999
Number of shared co-authors 0
Elie Traer
Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 2
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 1
Michael W Deininger
University of Utah Huntsman Cancer Institute
Career Start Year 1997
Number of shared co-authors 10
Changchun Deng
Center for Lymphoid Malignancies, Columbia University Medical Center
Career Start Year 1997
Number of shared co-authors 0
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1991
Number of shared co-authors 5
Ricky W Johnstone
The University of Melbourne
Career Start Year 1990
Number of shared co-authors 3
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 3
Lori S Hart
Children's Hospital of Philadelphia, USA. [2] Center for Childhood Cancer Research
Career Start Year 1987
Number of shared co-authors 0
Marcela Gronda
Princess Margaret Cancer Centre
Career Start Year 1985
Number of shared co-authors 0
Steven M Kornblau
The University of Texas MD Anderson Cancer Center
Career Start Year 1980
Number of shared co-authors 7
Brian J Druker
Oregon Health & Science University
Career Start Year 1978
Number of shared co-authors 6

Collaborators

Patrick Auberger
Universite Cote d'Azur, INSERM U5
Co-authored papers 39
Arnaud Jacquel
Universite Cote d'Azur, INSERM U5
Co-authored papers 19
Nina Fenouille
Universite Paris Cite, INSERM, CNRS
Co-authored papers 17
Kimberly Stegmaier
Dana-Farber Cancer Institute
Co-authored papers 16
Raphael Itzykson
Universite Paris Cite, INSERM, CNRS
Co-authored papers 14
Gabriela Alexe
Dana-Farber Cancer Institute
Co-authored papers 12
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Co-authored papers 10
Christopher F Bassil
Duke University School of Medicine Durham
Co-authored papers 9
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 8
Emmanuel Raffoux
Universite Paris Diderot
Co-authored papers 8
Yana Pikman
Dana Farber Cancer Institute
Co-authored papers 7
Lionel Ad??s
Assistance Publique des Hopitaux de Paris (AP-HP)
Co-authored papers 6
Herv?? Dombret
Institut de Recherche Saint-Louis, Universite de Paris
Co-authored papers 6
Reinaldo Dal Bello
Universite Paris Cite, INSERM, CNRS
Co-authored papers 6
Emmanuelle Clappier
Saint-Louis Hospital
Co-authored papers 6
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Co-authored papers 6
Daniel J DeAngelo
Dana-Farber Cancer Institute
Co-authored papers 6
Claude Preudhomme
Lille University Hospital, INSERM UMR-S7, CNRS UMR9020, Lille University.
Co-authored papers 6
Gaetano Sodaro
Universite Paris Cite, INSERM, CNRS
Co-authored papers 5
Thorsten Braun
Centre Hospitalier Universitaire Hopital Avicenne
Co-authored papers 5
Cl??mentine Chauvel
Universite Paris Cite, INSERM, CNRS
Co-authored papers 4
Angela Su
The Broad Institute of MIT and Harvard
Co-authored papers 4
Antoine Forget (CM4AI)
University of California San Francisco
Co-authored papers 4
Kris C Wood
Duke University
Co-authored papers 4
Justine Penneroux
Universite Paris Cite, INSERM, CNRS
Co-authored papers 3
Claude Gardin
Avicenne Hospital
Co-authored papers 3
Camille Lobry
INSERM U1170, Universite Paris Saclay
Co-authored papers 3
Kevin H Lin
Duke University
Co-authored papers 3
Jun Qi
Dana-Farber Cancer Institute
Co-authored papers 3
Jeannig Berrou
Universite Paris Cite, Institut de Recherche Saint-Louis
Co-authored papers 3
Release 1.2